Background: Apixaban (5 mg BID), dabigatran (available as 150 mg and 110 mg BID in Europe), and rivaroxaban (20 mg once daily) are 3 novel oral anticoagulants (NOACs) currently approved for stroke prevention in patients with atrial fibrillation (AF).
INTRODUCTION
Having atrial fibrillation (AF) increases a person's risk of experiencing stroke almost 5-fold. 1 Traditionally, prophylactic treatment in this setting has been based on vitamin K antagonists (VKAs), drugs that have been in use for 60 years 2 for their confirmed effectiveness in preventing thromboembolic events. 3 However, the well-known challenges in managing VKA therapy, such as monitoring requirements and the risk of hemorrhages, have resulted in such therapy being underused in the treatment of AF. 4 Given this context, the development of novel oral anticoagulants (NOACs), such as dabigatran, rivaroxaban, and apixaban, and their demonstrated efficacy in clinical trials have been encouraging with regard to addressing the need for improved stroke prevention treatments for patients with nonvalvular AF (NVAF). 2, 5 Dabigatran, a direct thrombin inhibitor, given at a dose of 110 mg BID, demonstrated noninferiority to warfarin in the primary end point of stroke and systemic embolism coupled with a significantly lower risk of major hemorrhage. 6 In addition, dabigatran 150 mg BID was superior to warfarin in the prevention of stroke and systemic embolism, with rates of major hemorrhage similar to warfarin. Rivaroxaban, an oral factor Xa inhibitor, was noninferior to warfarin in the prevention of stroke or systemic embolism, with no significant difference between the treatments in the risk of major bleeding. 7 Apixaban, another oral factor Xa and the third NOAC to receive European Union marketing authorization for the prevention of stroke and systemic embolism in AF, 8 is the only oral anticoagulant that has been shown to be superior to dose-adjusted warfarin in terms of reduction in the rates of stroke and systemic embolism, major bleeding, and all-cause mortality. 9 This evidence on NOACs underpins current guidelines from the European Society of Cardiology, which recommend the use of these drugs as "broadly preferable to VKA in the vast majority of patients with NVAF." 10 These drugs also offer the potential advantage of not requiring the anticoagulant monitoring needed for VKA therapy. The choice among NOACs, however, is not clear; this choice requires consideration of several practical issues, including patient characteristics, tolerability, and health economic outcomes. 2, 10, 11 A key means of capturing such elements is a cost-effectiveness analysis that investigates how the differences in costs associated with therapy relate to differences in benefits. This analysis can be conducted by using modeling techniques, which are commonly accepted as valid approaches to understanding the health economic consequences of different therapeutic alternatives. 1 Of note, many such analyses have compared an individual NOAC (ie, apixaban, rivaroxaban, dabigatran) versus warfarin by using data from randomized clinical trial data, [13] [14] [15] [16] [17] [18] [19] and several studies included all of the 3 NOACs from a US or Canadian perspective. [20] [21] [22] Crucially, however, no previous study has compared health economic outcomes between the 3 NOACs by using indirect treatment comparison data from a UK perspective conforming the drugs with their European labels.
From a health care payer's point of view, the absence of such data is a major gap in the evidence to inform decisions on resource allocation for NOACs. In particular, it is important to know whether the clinical advantages in terms of the efficacy and safety profile of apixaban over warfarin, as observed in randomized clinical trials, translate into health economic benefits, especially when compared with other NOACs, without head-to-head clinical trial data. The objective of the present study, therefore, was to assess the cost-effectiveness of apixaban (5 mg BID) versus the other NOACs (including dabigatran and rivaroxaban) approved for stroke prevention in patients with NVAF. The study was conducted from the perspective of the United Kingdom National Health Service.
METHODS
This study involved construction and use of an economic model to estimate long-term clinical and economic outcomes for patients with NVAF treated with apixaban, dabigatran, or rivaroxaban.
Model Design
The model used a Markov cohort approach. In the context of this study, such a model would conceptualize the course of AF by exploring what might happen over time to a hypothetical cohort of patients with the condition over a lifetime horizon. This analysis was performed by representing the disease course in terms of mutually exclusive health (or disease) states, their current health state (eg, NVAF in Figure 1 ) or experience an event (eg, ischemic stroke) that would cause them to move to at most 1 subsequent state (eg, ischemic stroke). The likelihood of each of these outcomes is known as its transition probability. These probabilities are built into the model and applied to the cohort during each cycle to calculate how the patients would be distributed between the thromboembolic and bleeding health states at the end of the cycle. This method in turn allows the model to calculate the related health care costs and benefits that will have accrued for the cohort as time has elapsed in the model.
A simplified schematic representation of the model structure for this study is shown in Figure 1 . The patient cohort is assumed to start in the NVAF health state, and time continues to elapse in the model until all the patients end up in the death state, 12 with calculation of the related accrued health care costs, life-years (LYs), and quality-adjusted life-years (QALYs) at the end of each model cycle. The cycle duration of 6 weeks was chosen deliberately to capture the possibility of events related to AF that occur within such a short time frame. The health states were either permanent, indicating that patients states that are identical for each of the 3 novel oral anticoagulant treatment options. All patients remain in the nonvalvular atrial fibrillation (NVAF) state until 1 of the following events occurs: stroke, bleeding, systemic embolism, myocardial infarction (MI), treatment discontinuation, or death. The transition probabilities of these events occurring depend on the treatment. For patients on second-line aspirin ("NVAF subsequent ASA"), the events are identical; however, patients cannot experience any further discontinuation. In each cycle, the cohort is subjected to risks (ie, transition probabilities) of experiencing the following events that are health states within the model: ischemic or unspecified stroke (referred to as "ischemic stroke"); ICH (with a defined percentage of these events being assumed to be hemorrhagic stroke); other major bleeds (major bleeds that are not ICHs and that are further classified as being either gastrointestinalor nongastrointestinal-related bleeds); clinically relevant nonmajor bleed; myocardial infarction (MI); systemic embolism; other cardiovascular hospitalization unrelated to the aforementioned events; or death.
Patients also have a defined risk of discontinuing their first-line treatment, which would cause them to transition to the "NVAF with subsequent aspirin treatment state," in which their risks of events in the following cycle are updated to those defined for their second-line aspirin treatment. Patients can enter this state after discontinuing their initial anticoagulant treatment owing to either ICH, other major bleeds, or other reasons unrelated to stroke, bleeding, MI, or systemic embolism. In this article, "other ICH" refers to ICHs that are not hemorrhagic strokes, with almost all cases being subdural hematoma.
For patients who experience nonfatal stroke (both ischemic and hemorrhagic) in the model, the severity of these events is classified into 1 of 3 categories of disability based on the modified Rankin Scale: mild, 0-2; moderate, 3 to 4; and severe, 5.
24 Patients experiencing their first nonfatal stroke can experience 1 recurrent stroke in subsequent cycles. Those experiencing a recurrent stroke transition to the most severe health state between primary and recurrent strokes. Recurrent strokes are modeled as permanent states (ie, patients in these states are assumed to have no subsequent events until they transition to the death state). Similarly, nonfatal MI and systemic embolism are also modeled as permanent health states accumulating decrements in utility and additional costs over a lifetime.
Population
The population represented in the analyses comprised patients with AF suitable for VKA therapy. The specific patient characteristics of the cohort (Table I) were matched to those of participants in ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation), 9 a study that had compared apixaban with warfarin in patients with NVAF.
Comparators
The model allowed comparison of predicted outcomes for the cohort with first-line use of each of the following NOAC regimens: apixaban (5 mg BID), 8 dabigatran 110 mg BID, dabigatran dose as recommended in the summary of product characteristics referred to as "dabigatran 150 mg" (ie, starting with 150 mg BID and switching to 110 mg BID at the age of 80 years), 25 and rivaroxaban (20 mg once daily).
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Risk of Clinical Events
The rates of various clinical events in patients taking apixaban were obtained from the ARISTOTLE trial. 9 To represent the comparative risks of such events for the other NOACs, hazard ratios (HRs) were applied to the rates for apixaban. These HRs were calculated by using an indirect treatment comparison of data from the trials of 3 drugs using the method of Bucher Where data was unavailable for novel oral anticoagulants, we assumed the same rate as for patients treated with apixaban and varied the inputs in the deterministic sensitivity analysis. ǁData for dabigatran and rivaroxaban were adjusted, using warfarin as a common arm, to the respective proportions observed in the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial. ¶ Assumed same proportion as for aspirin first-line as observed in the AVERROES (Apixaban Versus Acetylsalicylic Acid to Prevent Strokes) trial. #Dabigatran requires annual renal monitoring for patients with moderate to severe renal impairment as per the summary of product characteristics, 25 whereas this monitoring is not required for apixaban and rivaroxaban.
aspirin after discontinuation of initial NOAC treatment) were based on the analysis of a subgroup of patients in the AVERROES (Apixaban Versus Acetylsalicylic Acid to Prevent Strokes) 30 trial who had been previously prescribed, but discontinued, VKA and were then treated with aspirin instead (Table I) . Assumptions about the effects of treatment discontinuation on the occurrence of events are presented in Table II . The risks of ischemic stroke, bleeding, and MI were increased progressively by a factor of 1.46, 31 1.97, 32 and 1.30 33 per decade, respectively, to account for the increased likelihood of these events with aging.
The risk of recurrence postischemic or hemorrhagic stroke was assumed to be the same with all treatments and estimated to be 2.72 per 100 patient-years. 34 
Mortality
On the occurrence of each event, case-fatality rates based on data from trials ( Table I ) were applied to represent the risk of dying as a result of the episode. The case fatality rates for MI were obtained from published literature and estimated to be 10.8% in male subjects and 15.6% in female subjects. 35 Case fatality rates for other ICHs, other major bleeds, and systemic embolism were 13%, 2%, and 9.4%, respectively. Estimates were pooled from the AVERROES 30 and ARISTOTLE 9 trials and were assumed to be the same for all treatments (see Supplemental Appendix A and B in the online version at http://dx.doi.org/10.1016/j.clinthera.2013. 12.011).
All-cause mortality rates for apixaban excluding deaths attributable to stroke, bleeding, MI, and systemic embolism were derived from the ARISTO-TLE trial 9 and were applied to the cohort during the initial 1.8 years in the model (ie, a period matching the trial duration). These were assumed to be the same for the other NOACs. Beyond 1.8 years, mortality rates were modeled based on age-and gender-specific general mortality data in UK life tables. 36 In addition, an HR to account for the higher mortality associated with the following conditions was applied to the general life tables and to patients in each respective health state: AF (excluding excess mortality due to the events modeled), stroke, systemic embolism, or MI events (Table III) .
Utilities
Utility inputs (Table III) were obtained from a UKbased utility catalogue. 37 The disutility associated with the use of NOACs was assumed to be the same as that for aspirin. 
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Costs
Because the perspective adopted was that of the United Kingdom National Health Service health care payer, direct health care costs were included in the analysis. Costs in the model are reflected in 2011 British pounds and are categorized as either acute care costs relating to time spent in the hospital and rehabilitation facilities (assumed to be 2 weeks in the base case analysis described in the following discussion) or maintenance costs applied to the remainder of a patient's lifetime (Table IV) . Health and cost outcomes were discounted at 3.5% per year. 45 
Analyses
The analyses compared apixaban with the other NOACs in patients with NVAF suitable for VKA treatment. Specifically, this analysis involved predicting clinical and economic outcomes for a cohort of 1000 such patients over their lifetime, by calculating the LYs, QALYs, and costs accumulated over this period depending on which NOAC they were started on. In the primary analysis (the base case), the various predetermined data inputs described earlier were used in the model. To assess whether potential clinical advantages of apixaban over other NOACs (as suggested by trial data) would be worth the money spent on the drug, an incremental costeffectiveness ratio (ICER [additional cost per additional QALY gained]) was calculated for each comparison with the other 2 drugs. The ICER was then compared with the commonly accepted UK payers' willingness-to-pay threshold of £20,000 for each QALY gained 45 (ie, if the ICER of apixaban vs other another NOAC was below this threshold, then apixaban was considered a cost-effective treatment alternative). While on treatment *In absence of data to inform the hazard ratio of mortality for patients with systemic embolism, we assumed patients with systemic embolism would follow a similar mortality pattern to patients with nonvalvular atrial fibrillation. This assumption was tested in the deterministic sensitivity analysis. † Assumptions around the duration of these utility decrements were derived upon discussion with 2 cardiologists who were part of the research team (Drs. Lip and Dorian). ‡ Assumptions based on Freeman et al. 13 The sensitivity of the base case results was evaluated by conducting 1-way sensitivity analyses. These consisted of varying the model parameters, using their 95% CIs, one by one, while keeping all others constant and re-generating results to evaluate the robustness of the model's base case predictions in relation to uncertainties in the model parameters.
In addition to 1-way sensitivity analysis assessing the statistical uncertainty around the identified parameters, further scenario analysis was conducted to test uncertainties in structural assumptions as well as the plausibility and relevance of certain input data. These scenarios were determined by the 2 cardiologists that were part of the research team (Drs. Lip and Dorian) and specifically involved testing assumptions around the following: (1) treatment discontinuation; (2) stroke severity; (3) bleed severity; (4) costs and utilities of MI in current practice; and (5) utility decrement for ICH.
In addition to these analyses, probabilistic sensitivity analyses were performed by running 2000 iterations (or "simulations") of a 1000-patient cohort entering the model, with the values for key model inputs being varied between each iteration. The specific inputs for each iteration were obtained by random sampling from probability distributions of the parameters concerned. The fact that these inputs varied between iterations meant that every iteration would generate its own prediction of incremental costs and effectiveness and therefore its own ICER. The results of the probabilistic analysis were plotted on scatter-diagrams depicting the additional gains in QALYs, with apixaban compared with the other NOACs (on the x-axis) against the additional costs of the drug (on the y-axis). The probabilistic results were also used to generate a cost-effectiveness acceptability curve (CEAC), representing the proportion of simulations for which each treatment was the optimal treatment option at a given willingness-to-pay threshold. Warfarin and aspirin were included as treatment alternatives in the probabilistic analysis to assess the probability of apixaban being the most cost-effective option among all drugs used for preventing stroke in 
RESULTS
Base Case Analysis
For a cohort of 1000 patients considered over their lifetime, starting treatment with apixaban rather than another NOAC was predicted to result in fewer strokes (first and recurrent ischemic and hemorrhagic strokes), systemic embolisms, and cardiovascularrelated deaths ( Table V) . Patients treated with apixaban were also predicted to experience fewer major bleeds compared with dabigatran 150 mg and rivaroxaban. However, compared with dabigatran 110 mg, apixaban increased the number of major bleeds (first and recurrent hemorrhagic strokes, other ICHs, and other major bleeds) (15 episodes over the lifetime horizon).
In terms of therapeutic management costs, compared with dabigatran 110 mg, dabigatran 150 mg, and rivaroxaban, respectively, apixaban yielded additional anticoagulant (drug) and management costs of £713, £794, and £515 with average cost-offsets in monitoring and clinical event-related costs (lifetime reduction) of £249, £140, and £269; this led to a net increment in total cost over a projected lifetime of £464, £654, and £246. Apixaban's additional benefit in reducing the number of various clinical events led to (Table VI) .
One-Way Sensitivity Analyses and Scenario Analyses
Figures 2A through 2C present the results from the sensitivity analyses for the top 15 parameters that had the largest effect on the ICERs, in the order of their respective influence. The statistical uncertainty around model inputs not included on these tornado diagrams had negligible impact on the ICER results. Table VI presents the results of the scenario analysis around structural uncertainties as well as the plausibility and relevance of certain input data.
Compared with dabigatran 110 mg, the ICERs from all sensitivity analyses and scenarios varied from apixaban being dominant (ie, providing a higher number of QALYs at a lower cost) to the drug being associated with additional costs of £11,307 per QALY gained ( Figure 2A ; Table VI ). The comparison against dabigatran 150 mg showed that the ICERs from all scenarios varied from apixaban being dominant to its incurring an additional £32,717 per QALY gained ( Figure 2B ). In the comparisons between apixaban and rivaroxaban, the ICERs from all scenarios varied between apixaban dominating and being dominated ( Figure 2C ), with the latter scenario occurring when greater disutility was assigned to use of apixaban, despite the drug's anticipated advantage in relation to bleeding and adverse events ( Table I; Compared with the other NOACs, the 4 scenarios tested resulted in an ICER for apixaban above the commonly accepted threshold of £20,000 45 per QALY: (1) increasing the disutility of treatment with apixaban to 45 times that associated with other NOACs (thus equaling the disutility for patients treated with warfarin [ie, 0.013]); (2) decreasing the ischemic stroke rate for aspirin used as secondline therapy by 75% to 1.97 per 100 patientyears, thereby benefiting treatments with higher 
Probabilistic Sensitivity Analysis
Probabilistic sensitivity analysis demonstrated that apixaban was more effective at a small additional cost versus other NOACs over a lifetime horizon ( Figures  3A-3C ). The ICER was below the commonly assumed threshold of £20,000 per QALY gained 45 in 98% of trials comparing apixaban with dabigatran 110 mg, in 83% of trials compared with dabigatran 150 mg, and in 85% of trials compared with rivaroxaban. The results of the probabilistic analysis when all treatment comparators were included are shown as multi-way CEACs ( Figure 3D ). The CEAC, when generated by using the data on outcomes with NOACs from the indirect treatment comparisons and the data from direct head-to-head comparisons against warfarin and aspirin (see Supplemental Appendices B and C in the online version at http://dx.doi.org/10.1016/j.clinthera. 2013.12.011, indicated that apixaban was an optimal treatment choice representing the maximum net benefit over aspirin, warfarin, and the other NOACs, assuming payers are willing to pay £15,000 per QALY gained.
DISCUSSION
This study assessed the cost-effectiveness of apixaban as a first-line treatment in the prevention of stroke for patients with AF eligible for treatment with VKA, compared with other NOACs. Patients starting treatment with apixaban were predicted to experience fewer strokes and cardiovascular-related deaths compared with those taking the other NOACs. Although a cost-effectiveness analysis including comparisons of NOACs versus warfarin for AF has recently been published, [20] [21] [22] our study seems to be the first to be conducted from a UK perspective, also incorporating use of dabigatran as suggested by its European label. 25 Interestingly, an assessment limited to consideration of the indirect comparison data would give a favorable impression of dabigatran 150 mg compared with apixaban in terms of reduction of stroke risk (ie, HR versus apixaban ¼ 0.823); however, a broader overall consideration of efficacy, major bleeding, and tolerability profile extrapolated over a lifetime suggests that apixaban therapy would result in fewer strokes. This potential reduction in events (compared with other NOACs) is attributable to: (1) a switch to dabigatran 110 mg when patients reached age 80 years (as recommended by the summary of product characteristics), 25 where its protective effect was poorer than apixaban (HR VS apixaban ¼ 1.198); and (2) fewer patients discontinuing first-line treatment and starting second-line treatment (ie, aspirin) in the apixaban arm because of fewer major bleeds and, therefore, anticipated lower discontinuation rates. Consequently, lower discontinuation rates and assumed parity in drug acquisition costs resulted in apixaban-treated patients gaining a stroke prevention benefit over a longer period in the model at a small increase in pharmacologic treatment costs over the lifetime horizon. Bleeding outcomes were predicted to be less likely with apixaban in general, except for a slightly higher number of expected hemorrhagic strokes in the comparisons with dabigatran 110 mg and dabigatran 150 mg (27 vs 19 and 18, respectively [in the cohort of 1000 patients]), as well as a slight increase in the number of other major bleeds compared with dabigatran 110 mg (165 vs 157 [in the cohort of 1000 patients]). However, the overall benefit of apixaban outweighed these effects, as shown by an increase in LYs and QALYs in comparisons with both dabigatran and rivaroxaban in the analysis.
Our model was similar to those in earlier costeffectiveness studies assessing NOACs versus warfarin or among each other that used a Markov approach to represent potential stroke and bleeding events related to AF over a patient's lifetime. 13, [18] [19] [20] [21] 29 As with our study, some of these other trials examined the impact of treatment discontinuation. [18] [19] [20] [21] [22] 29, 13 However, caution is needed when comparing their results with those of our study, given the key differences in the study designs. In the most recent published studies, which compared all NOACs against warfarin and among each other, 20, 21 dabigatran 150 mg was not modeled according to the European label (ie, switching to 110 mg at age 80 years). 25 Had we adopted a similar approach, assuming patients remain on dabigatran 150 mg through their lifetime, apixaban would still be expected to be cost-effective with an ICER of £9913 under the base case assumptions. In addition, treatment discontinuation was not explicitly modeled. 20, 21 This limitation, in addition to the others, could account for the fact that these studies predicted (at odds with ours) a slightly higher number of QALYs gained in patients treated with dabigatran 150 mg compared with rivaroxaban (the result of the study excluding explicit modeling of treatment discontinuation, which was lower in patients treated with rivaroxaban than those treated with dabigatran 150 mg). By contrast, treatment discontinuation rates used in our study were those observed in the clinical trials, and the risk of further events in patients receiving second-line treatment with aspirin were based on secondary analysis of the subgroup of participants in the AVERROES 30 trial who had been "demonstrated" to be unsuitable for VKA (rather than "expected") at randomization (42% of the trial population). This approach allows more accurate modeling of treatment patterns and the clinical event risks in these patients, and is a key strength of our study. Furthermore, results were robust to changes around the assumptions of future treatment discontinuation rates. When setting treatment discontinuation rates for rivaroxaban, dabigatran 110 mg, and dabigatran 150 mg to equal those of apixaban beyond the duration of the trial (ie, 1.8 years), the ICERs decreased relative to the base case to £3296, £2417, and £9614, respectively, due to increase in costs among the NOACs arms; this outcome thus demonstrates that the base case results presented are conservative.
Additional important differentiators of our analysis from previous work include its more detailed modeling of mortality. This analysis was conducted with the use of mortality rates (for an initial period in the model equivalent to the duration of the ARISTOTLE 9 trial) and incorporation of an HR for increased mortality (beyond this initial period) for patients with AF compared with rates in the general population (in both cases, excluding mortality due to strokes, MI, and systemic embolism). Other models have assumed that patients with AF who had not experienced any events would follow mortality patterns similar to the general population, 3, 18, 21, 29 despite clear published evidence indicating that mortality of patients with AF is higher than that in the general population, even after adjusting for mortality rates due to stroke and MI.
39,50 Our study's incorporation of increased background mortality estimates represents a more cautious modeling approach, in that it reduced the predicted number of additional QALYs gained from treatment, therefore leading to higher estimates for the ICER (Table VI) . Furthermore, we included additional granularity and detail surrounding the severity of stroke and bleeding events, allowing these to be dependent on anticoagulant treatment based on data from the trials. Although ARISTOTLE 9 highlighted apixaban's favourable impact in reducing the severity of stroke events, potential differences in the severity of stroke events between the NOACs is much less certain. The assumption that ischemic stroke severity is dependent on treatment may have favoured apixaban. Had we assumed the same distribution of mRS in patients experiencing stroke events, regardless of treatment, the ICERs of apixaban versus the other NOACs would increase however remain below the £20,000 per QALY threshold.
As in previously published models, 18, 19, 21 our study included recurrent stroke events. However, in contrast to these earlier studies, our analysis assumed that NOACs would offer no additional prophylaxis for secondary stroke prevention because published trials of these treatments did not assess their efficacy in preventing recurrence of stroke. Consequently, recurrent stroke rates used in this study were assumed to be the same for all treatments. 34 Had we assumed that the efficacy of NOACs for secondary prevention is equal to the efficacy observed in primary prevention similarly to earlier cost-effectiveness studies, the results are likely to have been favorable for apixaban, given the lower number of strokes predicted in our model using primary prevention efficacy from the trials.
Various limitations also apply to our analysis. Although the utility estimates used in our study for all events were obtained from the same source (a standard EuroQol 5-Dimension catalogue) and validated by the 2 cardiologists who were part of the research team (Drs. Lip and Dorian), allowing consistent estimates between the various health states represented in the model, several utilities may be outdated with current practice. For example, the evolution of MI would suggest a higher baseline utility for these patients than those with a mild stroke; however, setting the utility of patients with MI to equal those with AF (ie, assuming no utility decrement associated with MI) or setting the HR of MI for all NOACs versus apixaban to 1 did not alter the model Clinical Therapeutics conclusions (Table VI) . Similarly, doubling the utility decrement for ICH had a negligible impact on results.
Importantly, event rates for each treatment were derived from clinical trial settings, and, consequently, the efficacy and safety observed may not reflect realworld outcomes. In the absence of head-to-head trials, an indirect treatment comparison based on the published NOAC studies was used to estimate the clinical event rates for other NOACS. Although several earlier indirect treatment comparisons have been conducted, 51-54 we performed further analysis to conform to model definitions and requirements. However, similar to previously conducted indirect treatment comparisons, this analysis did not control for the differences in patient baseline characteristics, CHADS 2 (congestive heart failure, hypertension, age Z75 years, diabetes mellitus, prior stroke or transient ischemic attack, or thromboembolism) risk profile, or time in therapeutic range. Also, the comparison did not correct for key differences between the designs of the trials, which was open-label for RE-LY 6 and double-blind for ROCKET-AF 7 and ARISTOTLE. 9 This presents a fundamental challenge in view of the heterogeneity of patient populations studied in each study (eg, ROCKET-AF studied a higher-risk population, 7 ). However, these variations seem more likely to have favored the other drugs rather than apixaban.
Lack of adjustment of baseline population characteristics can be considered conservative favoring rivaroxaban. In an indirect comparison assessing treatment effects among patients with a CHADS 2 score Z3, apixaban was found to reduce the risk of the primary efficacy outcome of stroke or systemic embolism by 23% compared with rivaroxaban (HR ¼ 0. Although we acknowledge the limitations associated with the methods of adjustment used in the indirect comparisons, we consider that these analyses provide a reasonable comparison of treatment effects and are of appropriate use in our model in the absence of head-to-head trials. Furthermore, results generated from this analysis are highly consistent with earlier indirect comparisons, [51] [52] [53] [54] with minor deviations attributed to use of odds ratios rather than HRs and use of updated RE-LY 6 data.
Overall, our predictions of the cost-effectiveness of apixaban could be considered cautious, given that the assumptions made in our study around input parameters and the differences between our model and previous models were likely to favor the comparator drugs.
CONCLUSIONS
The comprehensive assessment of the long-term efficacy, safety, and tolerability profile of apixaban in this study, generated through means of an economic model, predicted that the drug would provide an attractive alternative to other NOACs in the prevention of thromboembolic events in patients with AF. Specifically, it could offer favorable health benefits for a marginal increase in costs. In an economic environment of constrained health care resources, we believe that the findings of this study may help UK payers in making informed decisions that are in the best interests of patients who have NVAF. 
CONFLICTS OF INTEREST
OBJECTIVE
The following report details results of the indirect comparison analysis conducted to examine the relative efficacy and safety of the new oral anticoagulants (apixaban, dabigatran 110 mg, dabigatran 150 mg, and rivaroxaban). This report is primarily focused on reporting the hazard ratios (HRs) used as model inputs. Analyses were conducted by using event-rate data reported in the primary publications and related reports.
METHODS
The analysis is restricted to randomized controlled trials of pharmacologic prophylaxis of stroke prevention in patients with atrial fibrillation.
Population
The population covered in the analysis included: (1) patients with a risk of stroke and diagnosed with mildto-moderate nonvalvular atrial fibrillation; and (2) patients who were warfarin eligible.
Interventions for the Analysis
The following pharmacologic methods of prophylaxis were included: (1) apixaban; (2) rivaroxaban; and (3) dabigatran etexilate.
Outcomes
Outcomes Reported
The current analysis analyzed event-rate data for the following outcomes: ischemic or unspecified stroke; myocardial infarction; intracranial hemorrhage; other major bleeds; clinically relevant nonmajor (CRNM) bleed; and total discontinuations.
Studies Included in the Analyses
Three randomized controlled trials were included in the analyses: 
Statistical Analysis Direct and Indirect Meta-Analysis
Direct meta-analysis was conducted in Microsoft Excel. The HRs and their SEs were calculated by using standard formulae:
Indirect comparisons between apixaban and other treatments of interest via a common comparator were made by using the method of Bucher et al 4 and the HRs produced from the direct meta-analysis. The (indirect) HR between apixaban and the treatment of interest is given by:
with SE given by:
For some studies, rates were estimated where the rate events were not reported in the publication. The rates were estimated from the number of patients experiencing an outcome in cases in which the patient numbers were reported but the rate of first events was not reported. We calculated the probability of experiencing an outcome at the median follow-up point by dividing the number of first events by the number of patients randomized and converted this probability into an annual rate as: rate = -ln(1-probability)/median follow-up. This approximation accurately predicted the event rate for studies in which both the rate and number of patients with events were reported; this value is particularly approximate for studies in which patients were followed up for a fixed period of time.
The analysis of event-rate outcomes was conducted on an intent-to-treat (ITT) basis for efficacy outcomes and modified ITT (mITT) for safety outcomes. The analysis was conducted for efficacy end points in ITT populations (or number randomized and received treatment, if ITT figures are not reported). For adverse events, the safety population used in the analysis was the mITT population (number randomized and on treatment, with ITT data used if mITT data not reported). Similar analyses were performed for safety outcomes: ITT as the first analysis and per protocol as the second analysis.
Connolly et al 5 published an update to the original RE-LY publication that reported several additional primary efficacy and safety outcome events noted during routine clinical site closure visits after the database was locked. "Data from the update of the original RE-LY publication i.e. data reported in the updated 2010 publication was used in the primary analysis." 5 All the newly identified events were adjudicated in a blinded fashion and in accordance with the study protocol. All efficacy and safety analyses were reported on the ITT population for RE-LY. In the present analysis, efficacy results for ARISTOTLE are based on the ITT population. For the ROCKET-AF study, apart from primary efficacy outcome (stroke or systemic embolism), all secondary efficacy outcomes were reported on an on-treatment basis; although 14,264 patients were randomized in the ROCKET-AF study, 93 patients (rivaroxaban, n = 50; warfarin, n = 43) were excluded from all efficacy analyses before unblinding due to violations in Good Clinical Practice guidelines at 1 site. Therefore, the denominators used in the efficacy analysis reported here are as follows: rivaroxaban, n = 7081; warfarin, n = 7090.
The safety analyses for ARISTOTLE were based on a mITT population and included all patients who received at least 1 dose of the study drug and included all events from the time the first dose of a study drug was received until 2 days after the last dose was received. To align the reporting of safety results from ROCKET-AF with those from ARISTOTLE, the safety, as-treated population was used for the denominator (all patients who received at Supplemental least 1 dose of study drug and were followed up for events regardless of adherence to the protocol, while they were receiving the assigned study drug or within 2 days after discontinuation). Calculated events from dichotomous data were used in cases in which event rates were not reported in publications, and the calculated event-rate data were used in the analyses for up to 2 decimal places wherever possible.
RESULTS
Indirect Comparison Analysis (Warfarin-Eligible Patients)
The results reported in this section are based on the groups of warfarin-eligible patients for indirect comparison analysis.
Ischemic þ Unspecified Stroke (Calculated for ROCKET Publication)
Data for RE-LY are that reported in the updated 2010 publication. Calculated HRs (95% [CIs]) for the event ischemic or unspecified stroke are shown in Supplemental Table I .
Supplemental Table II presents a comparison of efficacy between treatments for warfarin-eligible patients: ischemic þ unspecified stroke (calculated for ROCKET Publication).
Myocardial Infarction
Data for RE-LY are that reported in the updated 2010 publication. Calculated HRs (95% CIs) for the event ischemic or unspecified stroke are shown in Supplemental Table III. Supplemental Table IV presets a comparison of efficacy between treatments for warfarin-eligible patients: myocardial infarction.
Intracranial Hemorrhage
Data for RE-LY are that reported in the updated 2010 publication. Calculated HRs (95% CIs) for the event ischemic or unspecified stroke are shown in Supplemental Table V. Supplemental Table VI presents a comparison of efficacy between treatments for warfarin-eligible patients: intracranial hemorrhage.
Other Major Bleeds (Major Bleeding Minus Intracranial Hemorrhage: On-Treatment Analysis)
Data for RE-LY are that reported in the updated 2010 publication. Calculated HRs (95% CIs) for the event ischemic or unspecified stroke are shown in Supplemental Table VII. Supplemental Table VIII presents a comparison of efficacy between treatments for warfarin-eligible patients: other major bleeds (calculated event rates).
Supplemental Table II *Intention-to-treat population (for ARISTOTLE, defined as all patients who underwent randomization and included all events from the time of randomization until the cutoff date for efficacy outcomes). † Events occurring through the cutoff date (includes follow-up period). ‡ Reported in the publication as the intention-to-treat population (number of patients randomized: rivaroxaban, n ¼ 7131; warfarin, n ¼ 7133). Patients excluded due to violations in Good Clinical Practice guidelines at 1 site that made the data unreliable. § Safety-on-treatment population, including patients who received Z1 dose of study drug and were followed up for events, regardless of adherence to the protocol, while they were receiving the assigned study drug or within 2 days after discontinuation. ‡ Patients who received at least 1 dose of study drug and were followed up for events regardless of adherence to protocol, while they were receiving the drug or within 2 days after discontinuation. § Events occurring during the treatment period or within 2 days after discontinuation (excluding follow-up). ǁ Patients who received at least 1 dose of study drug and events that occurred from the time the patients received the first dose of the study drug through 2 days after they received the last dose.
Supplemental
Supplemental Table VI HR ¼ hazard ratio. *Significant differences are shown in bold.
CRNM Bleed (ARISTOTLE Clinical Study Report Data) (Including Minor Bleed as Reported in RE-LY for Dabigatran)
Calculated HRs (95% CIs) for the event ischemic or unspecified stroke are shown in Supplemental  Table IX. Supplemental Table X presents a  comparison of efficacy between treatments for warfarin-eligible patients: CRNM bleed (minor bleed data used for RE-LY).
Total Discontinuations (Calculated Event Rates)
Calculated HRs (95% CIs) for the event ischemic or unspecified stroke are shown in Supplemental ‡ Patients who received at least 1 dose of study drug and events that occurred from the time the patients received the first dose of the study drug through 2 days after they received the last dose. § Calculated event rates with median on-treatment follow-up. ǁ Patients who received at least 1 dose of study drug and were followed up for events regardless of adherence to protocol, while they were receiving the drug or within 2 days after discontinuation. † Intention-to-treat population. ‡ Events occurring through the cutoff date (includes follow-up period). § Patients who received at least 1 dose of study drug and were followed up for events regardless of adherence to protocol, while they were receiving the drug or within 2 days after discontinuation. ǁ Events during the treatment period or within 2 days after discontinuation (as reported in the clinical study report). ¶ Patients who received at least 1 dose of study drug and events that occurred from the time the patients received the first dose of the study drug through 2 days after they received the last dose. 
Supplemental
METHODS
ARISTOTLE data were analyzed on a post hoc basis. Annualized event rates and related hazard ratios were computed for the relevant end points. The intentionto-treat (ITT) principle was used for the analysis of all end points except the safety end points (which were based on the modified ITT population). Stratified analyses were conducted across CHADS 2 (congestive heart failure, hypertension, age Z75 years, diabetes mellitus, prior stroke or transient ischemic attack, or thromboembolism) categories. 3 All risks were assessed in absolute terms or relative risk was computed by using hazard ratios for the event associated with warfarin versus apixaban. Drug-specific (ie, separately for apixaban as well as for warfarin) analysis of the center's time in therapeutic range (cTTR) was conducted by estimating the relative hazard of experiencing an event in a cTTR quartile versus that observed in the reference cTTR quartile of 52.38% r cTTR o66.02%. 4 This quartile was chosen as a reference quartile because it encompassed the median TTR of 66%. Mortality risk associated with reasons other than stroke, systemic embolism, bleeding, and myocardial infarction was assessed by deleting mortality associated with the aforementioned causes from all-cause mortality. Absolute mortality risk as well as relative hazard of mortality with warfarin versus apixaban for causes other than stroke, bleeding, and myocardial infarction was assessed.
Data were pooled from the treatment arms of ARISTOTLE and AVERROES (Apixaban Versus Acetylsalicylic Acid to Prevent Strokes) to assess fatality rates associated with intracranial hemorrhages, excluding hemorrhagic stroke and other major bleeds excluding any type of intracranial hemorrhages.
All analyses were conducted by using SAS version 9.2 (SAS Institute, Inc, Cary, North Carolina). Because this was a secondary analysis of ARISTOTLE analyses sets performed in a post hoc manner, no statistical significance was assessed.
Risk of an Event by cTTR Quartiles
Ischemic and Unspecified Stroke cTTR quartiles (as described in the ARISTOTLE clinical study report Table 7 .1.1.4) were used for the purpose of this analysis. 4 Supplemental Table I describes the risk of ischemic or unspecified stroke according to cTTR quartiles associated with apixaban. Supplemental Table II describes the risk of ischemic or unspecified stroke according to cTTR quartiles associated with warfarin.
Intracranial Hemorrhages
Similar to ischemic or unspecified stroke, risk of intracranial hemorrhages was assessed across cTTR quartiles, as described earlier. 4 Supplemental Tables III and IV describe the event rate and relative hazard ratios (HRs) for intracranial hemorrhage associated with apixaban and warfarin, respectively.
Other Major Bleeds Excluding Intracranial Hemorrhages
Other major bleeds were defined as major bleeds excluding intracranial hemorrhages. Supplemental Tables V and VI describe the event rate and relative HRs for other major bleeds associated with apixaban and warfarin, respectively.
Clinically Relevant Nonmajor Bleeding
Event rates and associated HRs associated with clinically relevant nonmajor bleeding are described in Supplemental Tables VII and VIII for apixaban and warfarin, respectively.
Z3 as specified in the seminal ARISTOTLE publication. As demonstrated in Supplemental 
AVERAGE RISK ASSOCIATED WITH BLEEDING EVENTS
The average risk of events, as described in Supplemental Table X , was observed in patients using apixaban versus warfarin in ARISTOTLE patients.
Hemorrhagic Stroke as a Part of Intracranial Hemorrhages
Hemorrhagic strokes comprised 77% of intracranial hemorrhages observed in apixaban-treated patients (40 of 52) versus 64% of intracranial hemorrhages observed in warfarin-treated patients (78 of 122). As stated earlier, the absolute event risk of experiencing intracranial hemorrhages was higher with warfarin versus apixaban.
Severity Distribution Associated with Strokes as Assessed by Modified Rankin Score
The distribution of stroke severity was observed by using modified Rankin Scale scores at 30-day follow-up postevent for apixaban Supplemental Table XII ). Patients with a modified Rankin Scale score of 6 represented fatality associated with the stroke event.
Ischemic or Unspecified Stroke
Supplemental Table XI presents the stroke severity classification associated with ischemic or unspecified stroke. 
Supplemental
Hemorrhagic Stroke
Supplemental Table XII presents the stroke severity classification associated with hemorrhagic stroke.
Treatment Discontinuation Rates Not Related to Absorbing States
Treatment discontinuation rates for reasons other than stroke or major bleeding were higher for warfarin versus those observed for apixaban. This resulted in greater HRs for warfarin versus apixaban both for treatment discontinuations related to: (1) excluding stroke or major bleeding; and (2) excluding stroke, major bleeding, myocardial infarction, or systemic embolism (Supplemental Table XIII ).
Fatality Rates Associated with Bleeding Episodes
Pooled data analyses, as described in Supplemental Table XIV, indicated 13% mortality associated with intracranial hemorrhage that did not manifest into hemorrhagic stroke. Pooled mortality rate for other major bleeds that were not intracranial in nature was 2%.
Mortality Risk Associated With Causes Other Than Stroke, Systemic Embolism, Major Bleeding, or Myocardial Infarction
Over the duration of the ARISTOTLE trial, apixaban had a nonstroke, non-systemic embolism, nonbleeding, and nonmyocardial infarction mortality rate of 3.0825 per 100 patient-years (n ¼ 528) versus warfarin, which had mortality rate of 3.3404 per 100 patient-years (n ¼ 568). The resulting hazard ratio was 1.0836 (95% CI, 0.962-1.220). 
SUPPLEMENTAL APPENDIX C
STUDY DESIGN
Study design and data collection associated with the AVERROES (ApixabanVersus Acetylsalicylic Acid to Prevent Strokes) trial have been described previously. 1 Seminal results, published by Connolly et al, 2 indicated that apixaban reduced the risk of stroke or systemic embolism without significantly increasing the risk of major bleeding or intracranial hemorrhage.
METHODS
AVERROES data were analyzed on a post hoc basis. Annualized event rates and related hazard ratios (HRs) were computed for the relevant end points.
The intention-to-treat (ITT) principle was used for the analysis of all end points except the safety end points (which were based on the modified ITT population). Stratified analyses were conducted across CHADS 2 (congestive heart failure, hypertension, age Z75 years, diabetes mellitus, prior stroke or transient ischemic attack, or thromboembolism) categories. 3 All risks were assessed in absolute terms or relative risk was computed by using HRs for the events associated with aspirin versus apixaban. Subgroup analyses were conducted in AVERROES participants who had previously used warfarin (vitamin K antagonists [VKAs]) but were not able to stay on the VKA due to their inability to maintain international normalized ratio control while on warfarin, because they experienced either bleeding or nonbleeding events while on warfarin, or for other similar reasons described in the AVERROES publication. 2 For the purposes of these analyses, the patients were labeled as the warfarin-unsuitable population (ie, proven unsuitable after experiencing warfarin use). Mortality risk associated with reasons other than stroke, systemic embolism, bleeding, and myocardial infarction was assessed by deleting mortality associated with the aforementioned causes from all-cause mortality. Absolute mortality risk as well as relative hazard of mortality with aspirin versus apixaban for causes other than stroke, bleeding, and myocardial infarction was assessed. Apixaban was used as a reference category for computing HRs associated with these events.
Data were pooled from ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) and AVERROES treatment arms to assess percentage of intracranial hemorrhages manifesting into hemorrhagic stroke, as well as fatality rates associated with intracranial hemorrhages (excluding hemorrhagic stroke and other major bleeds [excluding any type of intracranial hemorrhage]). For assessing distribution of hemorrhagic stroke across different levels of stroke severity, events were pooled across the apixaban and aspirin arms due to low absolute event rates in both arms.
All analyses were conducted by using SAS version 9.2 (SAS Institute, Inc, Cary, North Carolina). Because this was a secondary analysis of AVERROES analyses sets conducted in a post hoc manner, please refer to the article by Connolly et al for efficacy and safety results obtained based on prespecified primary and secondary hypotheses.
Risk of Ischemic or Unspecified Stroke According to CHADS 2 Score
Risk of ischemic or unspecified stroke was assessed at prespecified CHADS 2 categories of 0 to 1, 2, and Z3, as specified in the AVERROES publication. 2 As demonstrated in Supplemental Table I 
Risk of Experiencing Bleeding or Other Events
Supplemental Table II describes the absolute event rates (per 100 patient-years) and relative risk (as HRs) of experiencing an event when treated with aspirin versus apixaban.
Hemorrhagic Stroke as a Part of Intracranial Hemorrhages
Hemorrhagic strokes comprised 55% of intracranial hemorrhages observed in patients treated with 
Severity Distribution Associated With Strokes as Assessed by Modified Rankin Scale
The distribution of stroke severity was observed by using the modified Rankin Scale at 30-day followup postevent for apixaban versus aspirin. Patients with a modified Rankin Scale score of 6 represented fatality associated with the stroke event. Stroke severity distribution associated with ischemic or unspecified stroke according to treatment is described in Supplemental Table III . For hemorrhagic stroke, events were pooled across the apixaban and aspirin arms due to low absolute event rate in both arms for this analysis (Supplemental Table IV ).
Gastrointestinal Bleeding Rates as Part of Other Major Bleeding (Excluding Intracranial Hemorrhages)
Gastrointestinal bleeding comprised 35% (12 of 34) and 39% (7 of 18) of other major bleeding events (excluding intracranial hemorrhages) for apixaban and aspirin, respectively.
Treatment Discontinuation Rates Not Related to Absorbing States
Treatment discontinuation rate for reasons other than stroke or major bleeding were higher for aspirin versus that observed for apixaban, resulting into greater HRs for aspirin versus apixaban for treatment discontinuations not related to: (1) stroke or major bleeding; or (2) stroke, major bleeding, myocardial infarction, or systemic embolism (Supplemental Table V) .
Supplemental
Fatality Rates Associated With Bleeding Episodes
Pooled data analyses, as described in Supplemental Table VI, indicated 13% mortality associated with intracranial hemorrhage that did not manifest into hemorrhagic stroke. The pooled morality rate for other major bleeds that were not intracranial in nature was 2%.
Mortality Risk Associated With Causes Other Than Stroke, Systemic Embolism, Major Bleeding, or Myocardial Infarction
Over the duration of the AVERROES trial, the aspirin arm exhibited higher nonstroke, nonsystemic Supplemental 
